Altre lingue Dyne Therapeutics, Inc.

Azioni

DYN

US26818M1080

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 26/04/2024			Variaz. 5gg	Var. 1 gen.
24,73 ^USD	+4,37%		+3,65%	+85,94%

25/03	Il Presidente e Amministratore Delegato di Dyne Therapeutics Joshua Brumm si dimette, John Cox viene nominato successore; le azioni scendono del 7% prima della campanella	MT
25/03	Dyne Therapeutics, Inc. annuncia cambiamenti nella gestione	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer	27/03
Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium	27/03
Dyne Therapeutics President, CEO Joshua Brumm Resigns, John Cox Named Successor; Shares Drop 7% Pre-Bell	25/03
Dyne Therapeutics Announces CEO Transition	25/03
Dyne Therapeutics, Inc. Announces Management Changes	25/03
Dyne Therapeutics, Inc. Announces Chief Executive Officer Changes	25/03
Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days	13/03
Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days	13/03
Dyne Therapeutics Insider Sold Shares Worth $1,398,347, According to a Recent SEC Filing	05/03
Dyne Therapeutics's Q4 Net Loss Widens; Shares Down Pre-Bell	05/03
Dyne Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	05/03
Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights	05/03
Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights	05/03
Dyne Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	05/03
Dyne Therapeutics Insider Sold Shares Worth $2,895,519, According to a Recent SEC Filing	04/03
Dyne Therapeutics Insider Sold Shares Worth $811,865, According to a Recent SEC Filing	04/03
Dyne Therapeutics Insider Sold Shares Worth $357,296, According to a Recent SEC Filing	04/03
Dyne Therapeutics Insider Sold Shares Worth $19,626,903, According to a Recent SEC Filing	29/02
Dyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference	14/02
Dyne Therapeutics to Present at February Investor Conferences	01/02

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Dyne Therapeutics, Inc.

Azioni

DYN

US26818M1080

Altre lingue

Filtri